Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV2 Vaccine Formulations in Healthy Adults
NCT07416539Phase 1Active, not recruiting
- Sponsor
- Rokote Laboratories Finland
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rokote Laboratories Finland. Primary endpoints: Primary safety endpoints at Day 56 and Primary immunogenicity endpoint at Day 56. Started Feb 2026; status: active, not recruiting.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07416539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416539.